Citius Pharmaceuticals (NASDAQ:CTXR) posted its quarterly earnings data on Tuesday. The company reported ($0.07) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.03, Fidelity Earnings reports.
Shares of CTXR stock opened at $1.08 on Thursday. The stock has a 50-day moving average of $1.02 and a 200-day moving average of $1.07. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.37 and a quick ratio of 2.37. Citius Pharmaceuticals has a 1-year low of $0.42 and a 1-year high of $1.97.
CTXR has been the subject of several recent analyst reports. ValuEngine downgraded shares of Citius Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, December 1st. Zacks Investment Research upgraded Citius Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, November 30th. Finally, Dawson James reissued a “buy” rating on shares of Citius Pharmaceuticals in a report on Thursday, September 17th.
Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction tissue expander infections following breast reconstructive surgeries; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.
See Also: What is the S&P/ASX 200 Index?
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.